Anti Inflammatory News and Research

RSS

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

Chronic inflammation causes aging of the pituitary gland

Stem cell biologist Hugo Vankelecom (KU Leuven) and his colleagues have discovered that the pituitary gland in mice ages as the result of an age-related form of chronic inflammation. It may be possible to slow down this process or even partially repair it. The researchers have published their findings in PNAS.

15 Jun 2021

Alkaloids show potential as treatments for COVID-19

To further study these organic compounds, researchers from Kermanshah University of Medical Sciences, Iran, and Universidad de Santiago de Chile, Chile, reviewed the role of alkaloids as a potential antiviral, specifically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They presented the chemistry, plant sources, and antiviral effects of alkaloids and their anti-SARS-CoV-2 effect.

15 Jun 2021

Forkhead box O's potential therapeutic use in the treatment of COVID-19

In a recent study, Indian researchers from the Department of Biochemistry, University of Delhi, reviewed a possible vital coalition of FoxOs - the Forkhead Box O subfamily of protein transcription factors, with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the etiological agent of COVID-19 (coronavirus disease).

13 Jun 2021

Metformin prevents pulmonary or lung inflammation in animals infected with SARS-CoV-2

Metformin is a widely prescribed blood sugar-lowering drug. It is often used as an early therapy (in combination with diet and lifestyle changes) for type 2 diabetes, which afflicts more than 34 million Americans.

11 Jun 2021

Compound may block COVID-19 virus from entering lung cells, study reports

Research conducted at LSU Health New Orleans Neuroscience Center of Excellence reports that Elovanoids, bioactive chemical messengers made from omega-3 very-long-chain polyunsaturated fatty acids discovered by the Bazan lab in 2017, may block the virus that causes COVID-19 from entering cells and protect the air cells (alveoli) of the lung.

10 Jun 2021

Local anesthetic procaine inhibits SARS-CoV-2 in vitro

Research has shown that procaine and procaine-hydrochloride can reduce replication of SARS-CoV-2 and influenza A viruses in infected cells and reduce the production of cytokines by the viruses, making them potentially useful for treating COVID-19.

10 Jun 2021

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

Structural analogs of triterpenoids show strong inhibitory activity against coronaviruses

In a recent study published in the journal Pathogens, researchers carried out a molecular docking study for 17 structural analogs prepared from natural maslinic and oleanolic acids and screened them against SARS-CoV-2 main protease. They also experimentally validated the data by determining the half-maximal cytotoxic and inhibitory concentrations of each of the 17 compounds. The researchers investigated whether the compound with antiviral activity affected viral adsorption, replication, or viricidal effect using a plaque infectivity reduction assay.

9 Jun 2021

New bacterium shows promise for treating type 2 diabetes, obesity

It all started, when Patrice Cani, FNRS researcher at University of Louvain (UCLouvain), and his team repeatedly observed that a bacterium (called Subdoligranulum) is almost absent in obese and diabetic people, while it is systematically present in healthy people. So, they decided to take a closer look at this "family" of bacteria.

9 Jun 2021

Are women more likely to develop long COVID?

Researchers found different groups of symptoms persisting after coronavirus disease 2019 (COVID-19), with fatigue and higher IL-6 levels common in women. About 75% of the patients they treated were women, indicating a link between sex hormones and immune response.

8 Jun 2021

Treating critically ill COVID-19 patients with non-altered umbilical cord stem cells increases survival

Critically ill COVID-19 patients treated with non-altered stem cells from umbilical cord connective tissue were more than twice as likely to survive as those who did not have the treatment, according to a study published today in STEM CELLS Translational Medicine.

8 Jun 2021

Chemical engineers devise a simpler process to incorporate hydrophobic drugs into tablets

About 60 percent of drugs on the market have hydrophobic molecules as their active ingredients. These drugs, which are not soluble in water, can be difficult to formulate into tablets because they need to be broken down into very small crystals in order to be absorbed by the human body.

8 Jun 2021

Study reports safety, efficacy of targeted treatment for IgA nephropathy

IgA nephropathy (IgAN) is a chronic kidney disease occurring in young adults and is one of the most common reasons for kidney transplantation in this age group.

7 Jun 2021

Natural products show promise against COVID-19 via iron chelation

Researchers at the University of Catania in Italy investigated whether natural compounds could prevent disease progression. Their study published in the Journal of Clinical Medicine found that iron chelators and protease inhibitors can counteract SARS-CoV-2 infection.

7 Jun 2021

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).

7 Jun 2021

Researchers identify a bacterium with anti-SARS-CoV-2 activity in vitro: Dolosigranulum pigrum

As intensive efforts are on to counter the virus, a new study by an international team of researchers reports the unexpected success of a bacterium in modulating the immune response in the airway and protecting the cells against infection with this virus.

7 Jun 2021

The great promise of antiviral peptides against SARS-CoV-2

A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.

7 Jun 2021

High baseline levels of inflammatory cytokines linked to thrombotic events in patients with COVID-19

In a recent open-access paper published in the Journal of Clinical Medicine, researchers from Iran and Germany show that high baseline levels of inflammatory cytokines measured during admission put patients with coronavirus disease (COVID-19) at increased risk of developing coagulopathy, thrombotic events – and even death.

6 Jun 2021

Metformin potently inhibits SARS-CoV-2-induced cytokine release in monocytes

An interesting new bioRxiv* preprint reports the suppression of monocyte glycolysis and cytokine production when exposed to the virus, following pretreatment with the commonly used drug, metformin.

6 Jun 2021

Anti Inflammatory News and Research

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

Chronic inflammation causes aging of the pituitary gland

Alkaloids show potential as treatments for COVID-19

Forkhead box O's potential therapeutic use in the treatment of COVID-19

Metformin prevents pulmonary or lung inflammation in animals infected with SARS-CoV-2

Compound may block COVID-19 virus from entering lung cells, study reports

Local anesthetic procaine inhibits SARS-CoV-2 in vitro

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

Structural analogs of triterpenoids show strong inhibitory activity against coronaviruses

New bacterium shows promise for treating type 2 diabetes, obesity

Are women more likely to develop long COVID?

Treating critically ill COVID-19 patients with non-altered umbilical cord stem cells increases survival

Chemical engineers devise a simpler process to incorporate hydrophobic drugs into tablets

Study reports safety, efficacy of targeted treatment for IgA nephropathy

Natural products show promise against COVID-19 via iron chelation

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

Researchers identify a bacterium with anti-SARS-CoV-2 activity in vitro: Dolosigranulum pigrum

The great promise of antiviral peptides against SARS-CoV-2

High baseline levels of inflammatory cytokines linked to thrombotic events in patients with COVID-19

Metformin potently inhibits SARS-CoV-2-induced cytokine release in monocytes

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News